We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

87 hedge funds and large institutions have $263M invested in Relmada Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

606% more call options, than puts

Call options by funds: $5.55M | Put options by funds: $785K

200% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 12

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

2% more funds holding

Funds holding: 85 → 87 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.79% less ownership

Funds ownership: 59.19% → 57.4% (-1.8%)

17% less capital invested

Capital invested by funds: $316M → $263M (-$53.7M)

Holders
87
Holders Change
+2
Holders Change %
+2.35%
% of All Funds
1.52%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
36
Reduced
12
Closed
13
Calls
$5.55M
Puts
$785K
Net Calls
+$4.76M
Net Calls Change
-$3M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$11.3M
2
Millennium Management
Millennium Management
New York
+$6.38M
3
GTC
Ghost Tree Capital
New York
+$5.35M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.83M
5
BBA
Baker Bros. Advisors
New York
+$3.33M

Top Sellers

1
ACA
Avoro Capital Advisors
New York
-$29.9M
2
IC
Ikarian Capital
Texas
-$7.48M
3
BlackRock
BlackRock
New York
-$6.96M
4
TA
Tiedemann Advisors
New York
-$1.78M
5
Charles Schwab
Charles Schwab
California
-$1.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$1.39M +$1.08M +40,239 +310%
Charles Schwab
27
Charles Schwab
California
$1.08M -$1.55M -57,910 -58%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$913K -$889K -33,231 -49%
SAG
29
Spotlight Asset Group
Illinois
$793K – – –
MHC
30
Meyer Handelman Company
New York
$744K – – –
PAM
31
Pegasus Asset Management
New York
$707K – – –
Swiss National Bank
32
Swiss National Bank
Switzerland
$681K +$24.1K +900 +4%
IC
33
Ikarian Capital
Texas
$544K -$7.48M -279,464 -93%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$527K – – –
CL
35
CSS LLC
Illinois
$481K +$491K +18,359 New
PPA
36
Parametric Portfolio Associates
Washington
$475K +$485K +18,117 New
AllianceBernstein
37
AllianceBernstein
Tennessee
$469K – – –
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$463K -$82.1K -3,068 -15%
MAM
39
Martingale Asset Management
Massachusetts
$463K +$270K +10,100 +135%
JF
40
Jump Financial
Illinois
$443K +$452K +16,900 New
Deutsche Bank
41
Deutsche Bank
Germany
$432K +$21.9K +820 +5%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$415K +$18K +673 +4%
Renaissance Technologies
43
Renaissance Technologies
New York
$406K +$415K +15,500 New
WIA
44
World Investment Advisors
California
$372K +$5.35K +200 +1%
CSS
45
Cubist Systematic Strategies
Connecticut
$369K +$344K +12,841 +1,053%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$342K +$1.04K +39 +0.3%
Bank of America
47
Bank of America
North Carolina
$322K +$163K +6,084 +98%
JP Morgan Chase
48
JP Morgan Chase
New York
$283K +$9.21K +344 +3%
IBT
49
International Biotechnology Trust
United Kingdom
$261K +$268K +10,000 New
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$257K +$7.6K +284 +3%
1
2
3 4

RLMD Hedge Fund Activity: Q3 2021 in Review

87 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q3 2021, worth a combined $263M — down 17% from $316M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new RLMD positions and 13 closed out — a net gain of 2 holders — while 36 added to existing stakes and 12 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $11.3M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $29.9M sold.

  • 87 institutional investors held Relmada Therapeutics (RLMD) as of Q3 2021, up from 85 in Q2 2021.
  • Funds reported $263M of Relmada Therapeutics stock for Q3 2021, down 17% quarter-over-quarter.
  • 15 funds opened new Relmada Therapeutics positions in Q3 2021 and 13 closed out, a net change of +2 holders.
  • The largest Relmada Therapeutics buyer in Q3 2021 was Morgan Stanley, an estimated $11.3M added.
  • The largest Relmada Therapeutics seller in Q3 2021 was Avoro Capital Advisors, an estimated $29.9M sold.

Based on aggregated 13F filings for Q3 2021.